These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11132541)

  • 21. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
    [No Abstract]   [Full Text] [Related]  

  • 22. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Colorectal cancer in inflammatory bowel disease].
    Henriksen M; Moum B
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Left-sided ulcerative colitis.
    Haghighi DB; Lashner BA
    Gastroenterol Clin North Am; 2004 Jun; 33(2):271-84, ix. PubMed ID: 15177538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute pancreatitis after long-term 5-aminosalicylic acid therapy.
    Fernández J; Sala M; Panés J; Feu F; Navarro S; Terés J
    Am J Gastroenterol; 1997 Dec; 92(12):2302-3. PubMed ID: 9399776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal dosing of 5-aminosalicylic acid: 5 decades of choosing between politicians.
    Bickston SJ; Cominelli F
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):3-4. PubMed ID: 15017510
    [No Abstract]   [Full Text] [Related]  

  • 29. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
    Fallingborg JF
    Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
    Desreumaux P; Ghosh S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():2-9. PubMed ID: 16939423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ulcerative colitis. Cancer prevention].
    Schmiegel W; Pox C; Kroesen A
    Z Gastroenterol; 2004 Sep; 42(9):1014-8. PubMed ID: 15455276
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
    Johnson LK; Pruitt RE; Green JR
    Am J Gastroenterol; 2003 Jan; 98(1):216-9. PubMed ID: 12526969
    [No Abstract]   [Full Text] [Related]  

  • 34. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV; Cohen RD
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
    Farrell RJ; Peppercorn MA
    Am J Gastroenterol; 2002 Jun; 97(6):1283-5. PubMed ID: 12094839
    [No Abstract]   [Full Text] [Related]  

  • 36. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ
    J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CANCERPREVENTIVE IN ULCERATIVE COLITIS.
    Podolskaya DV; Shapina MV; Khalif IL
    Eksp Klin Gastroenterol; 2016; (8):4-8. PubMed ID: 29874428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
    Rubin DT; LoSavio A; Yadron N; Huo D; Hanauer SB
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1346-50. PubMed ID: 17059900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.